drugdeliverybusiness14d
Abbott Diabetes spurs growth with 22.7% uptick in CGM revenue, expects more insulin pump connectivity
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.
pharmaphorum5d
Real-time Abbott glucose monitor available to NHS after UK launch
Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...